DE60124400D1 - Verwendung eines betablockers zur behandlung von atherosklerose - Google Patents

Verwendung eines betablockers zur behandlung von atherosklerose

Info

Publication number
DE60124400D1
DE60124400D1 DE60124400T DE60124400T DE60124400D1 DE 60124400 D1 DE60124400 D1 DE 60124400D1 DE 60124400 T DE60124400 T DE 60124400T DE 60124400 T DE60124400 T DE 60124400T DE 60124400 D1 DE60124400 D1 DE 60124400D1
Authority
DE
Germany
Prior art keywords
betablocker
atherosclerosis
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60124400T
Other languages
English (en)
Other versions
DE60124400T2 (de
Inventor
Goeran Berglund
John Wikstrand
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of DE60124400D1 publication Critical patent/DE60124400D1/de
Application granted granted Critical
Publication of DE60124400T2 publication Critical patent/DE60124400T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
  • Pyridine Compounds (AREA)
DE60124400T 2000-06-22 2001-06-15 Verwendung eines betablockers zur behandlung von atherosklerose Expired - Fee Related DE60124400T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0002354 2000-06-22
SE0002354A SE0002354D0 (sv) 2000-06-22 2000-06-22 New formulation
PCT/SE2001/001380 WO2001097751A2 (en) 2000-06-22 2001-06-15 New formulation comprising a betablocker and optionally a cholesterol-lowering agent

Publications (2)

Publication Number Publication Date
DE60124400D1 true DE60124400D1 (de) 2006-12-21
DE60124400T2 DE60124400T2 (de) 2007-10-31

Family

ID=20280209

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60124400T Expired - Fee Related DE60124400T2 (de) 2000-06-22 2001-06-15 Verwendung eines betablockers zur behandlung von atherosklerose

Country Status (28)

Country Link
US (2) US20030191177A1 (de)
EP (1) EP1296716B1 (de)
JP (1) JP2003535875A (de)
KR (1) KR20030010750A (de)
CN (1) CN1437484A (de)
AR (1) AR028699A1 (de)
AT (1) ATE344675T1 (de)
AU (1) AU2001274766A1 (de)
BG (1) BG107373A (de)
BR (1) BR0111790A (de)
CA (1) CA2411100A1 (de)
CZ (1) CZ20024181A3 (de)
DE (1) DE60124400T2 (de)
EE (1) EE200200703A (de)
ES (1) ES2274892T3 (de)
HK (1) HK1054508A1 (de)
HU (1) HUP0302371A3 (de)
IL (1) IL153245A0 (de)
IS (1) IS6653A (de)
MX (1) MXPA02012957A (de)
NO (1) NO20026177L (de)
NZ (1) NZ523188A (de)
PL (1) PL360484A1 (de)
RU (1) RU2271802C2 (de)
SE (1) SE0002354D0 (de)
SK (1) SK18072002A3 (de)
WO (1) WO2001097751A2 (de)
ZA (1) ZA200209908B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1722780A4 (de) * 2003-11-26 2008-12-17 Univ Duke Verfahren zur prävention oder behandlung von glaukom
KR100582347B1 (ko) * 2004-12-30 2006-05-22 한미약품 주식회사 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법
KR100836321B1 (ko) 2006-10-31 2008-06-09 현대자동차주식회사 차량용 모니터 장치

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175187A (en) * 1989-03-06 1992-12-29 Soorianarain Baligadoo Synergistic compositions for the treatment of coronary insufficiency and methods of use thereof
US5455269A (en) * 1989-03-06 1995-10-03 Baligadoo; Soorianarain Synergistic compositions of amiodarone and beta blockers
WO1992016197A1 (en) * 1991-03-18 1992-10-01 Sepracor Inc. Composition and method containing optically pure (s) metoprolol
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
NO177455C (no) * 1993-06-04 1995-09-20 Gerrit Elmenhorst Anordning ved apparat for fremstilling av brannslukkende skum
WO1997038694A1 (en) * 1996-04-17 1997-10-23 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
SE9602762D0 (sv) * 1996-07-12 1996-07-12 Astra Ab Carton and blank for forming the same
US5998458A (en) * 1997-06-25 1999-12-07 University Technology Corporation Method of treating heart failure
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.
EP1140187B1 (de) * 1998-12-23 2003-09-03 G.D. Searle LLC. Kombinationen einem ibat inhibitor und einem mtp inhibitor für kardiovaskuläre indikationen

Also Published As

Publication number Publication date
NO20026177D0 (no) 2002-12-20
JP2003535875A (ja) 2003-12-02
CA2411100A1 (en) 2001-12-27
EP1296716B1 (de) 2006-11-08
RU2271802C2 (ru) 2006-03-20
BR0111790A (pt) 2003-05-20
IL153245A0 (en) 2003-07-06
HK1054508A1 (zh) 2003-12-05
ATE344675T1 (de) 2006-11-15
DE60124400T2 (de) 2007-10-31
MXPA02012957A (es) 2003-05-15
HUP0302371A3 (en) 2007-03-28
HUP0302371A2 (hu) 2003-11-28
US20060252814A1 (en) 2006-11-09
IS6653A (is) 2002-12-11
EE200200703A (et) 2004-08-16
NZ523188A (en) 2006-06-30
PL360484A1 (en) 2004-09-06
NO20026177L (no) 2002-12-20
WO2001097751A3 (en) 2002-03-28
CN1437484A (zh) 2003-08-20
US20030191177A1 (en) 2003-10-09
SE0002354D0 (sv) 2000-06-22
EP1296716A2 (de) 2003-04-02
AR028699A1 (es) 2003-05-21
ZA200209908B (en) 2004-03-05
CZ20024181A3 (cs) 2003-04-16
BG107373A (bg) 2003-09-30
WO2001097751A2 (en) 2001-12-27
KR20030010750A (ko) 2003-02-05
SK18072002A3 (sk) 2003-08-05
AU2001274766A1 (en) 2002-01-02
ES2274892T3 (es) 2007-06-01

Similar Documents

Publication Publication Date Title
ATE265860T1 (de) Impstoff zur behandlung von atherosclerosis
ATE394103T1 (de) Verwendung von rosuvastatin (zd-4522) zur behandlung von heterozygoter familiärer hypercholesterolämie
DE60035378D1 (de) Gerät zur Behandlung von Bandscheiben
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
ATE275145T1 (de) Chinazolinderivate zur behandlung von tumoren
ATE538096T1 (de) Pyridinon-derivate zur behandlung von arteriosklerose
DE60114580D1 (de) Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
DE69924750D1 (de) Gerät zur thermischen behandlung von gewebe
DE50009504D1 (de) Verwendung von retigabin zur behandlung von neuropathischen schmerzen
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60019158D1 (de) Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien
DE60029033D1 (de) Verfahren zur Behandlung von Tissuepapier
DE60234760D1 (de) Phenylindole zur behandlung von hiv
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE69936890D1 (de) Vorrichtung zur Behandlung von Ischämie
ATE279386T1 (de) Retinoide zur behandlung von emphysem
DE50014041D1 (de) Verwendung von epinastin zur behandlung von allergischer rhinitis/konjunktivitis
ATE254913T1 (de) Diacerein zur behandlung von psoriasis
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
DE60030861D1 (de) Verwendung von escitalopram zur Behandlung von generalisierten Angstzuständen
DE69943089D1 (de) Methode zur behandlung von staphylokokkeninfektionen
DE60104791D1 (de) Cyclobutendion-Derivate zur Behandlung von Artherosclerose
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
DE60238765D1 (de) Carbamatverbindungen zur behandlung von schmerz

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee